CN101293063B - Composition for treating climacteric syndrome, preparation and quality control method thereof - Google Patents
Composition for treating climacteric syndrome, preparation and quality control method thereof Download PDFInfo
- Publication number
- CN101293063B CN101293063B CN2007100987719A CN200710098771A CN101293063B CN 101293063 B CN101293063 B CN 101293063B CN 2007100987719 A CN2007100987719 A CN 2007100987719A CN 200710098771 A CN200710098771 A CN 200710098771A CN 101293063 B CN101293063 B CN 101293063B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- solution
- root
- adds
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a pharmaceutical composition for treating women menopausal syndrome, a preparation method and a quality control method. The pharmaceutical composition of the invention is composed of pharmaceutical raw materials of glossy privet fruit, palmleaf raspberry fruit, south dodder seed, tuber fleeceflower root, cortex lycii radicis, ladybell root, dwarf lilyturf tuber, baical skullcap root, rehmannia root, white paeony root, red paeony, Chinese angelica, nacre and blackend swallowwort root; the preparation method is that: the pharmaceutical raw materials are selected, ground into fine powder, screened and evenly mixed; every 100g of powder is added by 42g of refining honey and appropriate amount of water, pill making and low-temperature drying are carried out, thus preparing the pharmaceutical composition. The preparation method adopts high performance liquid chromatography to carry out the content measurement on paeoniflorin. The pharmaceutical composition of the invention has good efficacy for treating women menopausal syndrome.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation method thereof and method of quality control, particularly relate to a kind of Chinese medicine composition for the treatment of women's climacteric syndrome and preparation method thereof and method of quality control.
Background technology
Women's climacteric syndrome is meant the women before and after menopause, because the ovarian function decline causes endocrinopathy, the a series of syndrome that vegetative nerve functional disturbance produced, as hectic fever, flush is perspired, lather, blahs aypnia, abnormal feeling is capricious sometimes, for no reason cry and laugh at, have like the insane.The traditional Chinese medical science is thought the generation of this disease, be since the women over seventy-seven, the kidney qi degradation, dash appoint lose empty, asthenia of essence and blood, or because of depressed emotion, the dark consumption of battalion, cause the imbalance of yin and yang of kidney, and then influence the heart, liver, all dysfunctions of spleen, thereby all signs of climacteric syndrome occur.
Doctor trained in Western medicine adopts complementing estrogen when this type of disease of treatment, because climacteric syndrome goes down or loses because of women's ovary merit palace and causes, so, if at this moment complementing estrogen replaces the estrogen of human body shortage to play a role, it can slow down or cure fully a series of symptoms that climacteric women causes because of estrogen deficiency.By can " recovering " function of ovary for women's complementarity hormone, thereby alleviate involutional various symptom.But some women can not use controversies in hormone replacement in the elderly as fibroid etc. because of various reasons, and patients with uterine myoma uses estrogen might become cancer.The Western medicine that other alleviates menopause symptom also all can have side effects to patient body, can not use for a long time.
This type of disease of Chinese traditional treatment generally speaking is to be guiding principle with kidney yin, kidney yang dysequilibrium, and dialectical main points are that yin-yang attribute will be distinguished.Aspect the selection medicine, to have the medicine of enriching yin and nourishing kidney, nourishing qi and blood, promoting blood circulation for regulating menstruation, the invigorating the spleen effect of drying, very useful to involutional women, can promote the endocrine of climacteric women to regulate, help health to set up new balance rapidly, recover normal physiological status.As enriching yin and nourishing kidney, can improve the unsettled situation of suspection that climacteric women occurs; Promoting blood circulation for regulating menstruation, nourishing qi and blood are to pointed therapeutic actions of disease such as this women's of climacteric easy perspiration, hectic fever, insomnia and dreamful sleep, dizziness headaches.Chinese medicine is aspect the treatment women's climacteric syndrome, and not only curative effect is relatively good, and has avoided using the adverse consequences that estrogen brought.
Summary of the invention
The object of the invention is to provide a kind of Chinese medicine composition for the treatment of women's climacteric syndrome;
The object of the invention also is to provide a kind of Chinese medicine composition preparation method who treats women's climacteric syndrome;
The object of the invention also is to provide a kind of method of quality control for the treatment of the Chinese medicine composition of women's climacteric syndrome.
The present invention seeks to be achieved through the following technical solutions:
The Chinese medicine composition of treatment women's climacteric syndrome of the present invention is to be made by the bulk drug of following weight ratio:
The fruit of glossy privet (wine is processed) 10-60 weight portion raspberry 10-50 weight portion
The seed of Chinese dodder 10-50 weight portion fleece-flower root (black soya bean wine is processed) 10-50 weight portion
Root bark of Chinese wolf-berry 10-60 weight portion adenophora tetraphylla 10-60 weight portion
The tuber of dwarf lilyturf 10-50 weight portion root of large-flowered skullcap 10-60 weight portion
Glutinous rehmannia 10-60 weight portion root of herbaceous peony 20-100 weight portion
Red spoon 10-60 weight portion Radix Angelicae Sinensis 10-50 weight portion
Mother-of-pearl 20-100 weight portion radix cynanchi atrati 10-60 weight portion;
The above-mentioned raw materials optimum ratio is:
The fruit of glossy privet (wine is processed) 40 weight portion raspberries 30 weight portions
The seed of Chinese dodder 30 weight portion fleece-flowers root (black soya bean wine is processed) 30 weight portions
The root bark of Chinese wolf-berry 30 weight portion adenophora tetraphyllas 30 weight portions
The tuber of dwarf lilyturf the 20 weight portion roots of large-flowered skullcap, 30 weight portions
The glutinous rehmannia 30 weight portion root of herbaceous peonys 60 weight portions
Red spoon 30 weight portion Radix Angelicae Sinensis 30 weight portions
Mother-of-pearl 60 weight portion radix cynanchi atratis 40 weight portions;
The Chinese medicine composition of treatment women's climacteric syndrome of the present invention can be made by the bulk drug of following weight ratio:
The fruit of glossy privet (wine is processed) 10-60 weight portion raspberry 10-50 weight portion
The seed of Chinese dodder 10-50 weight portion fleece-flower root (black soya bean wine is processed) 10-50 weight portion
Root bark of Chinese wolf-berry 10-60 weight portion adenophora tetraphylla 10-60 weight portion
The tuber of dwarf lilyturf 10-50 weight portion root of large-flowered skullcap 10-60 weight portion
Glutinous rehmannia 10-60 weight portion root of herbaceous peony 20-100 weight portion
Red spoon 10-60 weight portion Radix Angelicae Sinensis 10-50 weight portion
Mother-of-pearl 20-100 weight portion radix cynanchi atrati 10-60 weight portion
Wind-weed 10-60 weight portion tortoise plastron 10-60 weight portion
Reticulate millettia 20-100 weight portion fruit of Chinese wolfberry 10-50 weight portion;
The above-mentioned raw materials optimum ratio is:
The fruit of glossy privet (wine is processed) 40 weight portion raspberries 30 weight portions
The seed of Chinese dodder 30 weight portion fleece-flowers root (black soya bean wine is processed) 30 weight portions
The root bark of Chinese wolf-berry 30 weight portion adenophora tetraphyllas 30 weight portions
The tuber of dwarf lilyturf the 20 weight portion roots of large-flowered skullcap, 30 weight portions
The glutinous rehmannia 30 weight portion root of herbaceous peonys 60 weight portions
Red spoon 30 weight portion Radix Angelicae Sinensis 30 weight portions
Mother-of-pearl 60 weight portion radix cynanchi atratis 40 weight portions
The wind-weed 30 weight portion tortoise plastrons 15 weight portions
The reticulate millettia 50 weight portion fruits of Chinese wolfberry 20 weight;
The Chinese medicine composition of treatment women's climacteric syndrome of the present invention can be made by the bulk drug of following weight ratio:
The fruit of glossy privet (wine is processed) 10-60 weight portion raspberry 10-50 weight portion
The seed of Chinese dodder 10-50 weight portion fleece-flower root (black soya bean wine is processed) 10-50 weight portion
Root bark of Chinese wolf-berry 10-60 weight portion adenophora tetraphylla 10-60 weight portion
The tuber of dwarf lilyturf 10-50 weight portion root of large-flowered skullcap 10-60 weight portion
Glutinous rehmannia 10-60 weight portion root of herbaceous peony 20-100 weight portion
Red spoon 10-60 weight portion Radix Angelicae Sinensis 10-50 weight portion
Mother-of-pearl 20-100 weight portion radix cynanchi atrati 10-60 weight portion
Wind-weed 10-60 weight portion tortoise plastron 10-50 weight portion
Reticulate millettia 20-100 weight portion fruit of Chinese wolfberry 10-50 weight portion
Stem of noble dendrobium 10-60 weight portion chrysanthemum 10-60 weight portion
Eclipta 20-100 weight portion mulberry leaf 10-50 weight portion
Spina date seed (stir-fry) 10 weight portions;
Composition of the present invention technology adding auxiliary material is routinely made clinical acceptable forms such as tablet, capsule, oral liquid, dripping pill, spray, granule; Described auxiliary material comprises solvent, disintegrant, flavouring, antiseptic, colorant, bonding agent, lubricant, matrix etc.
The preparation method of Chinese medicinal composition preparation of the present invention is:
Choose described bulk drug, partly or entirely be ground into fine powder, all the other flavour of a drug extract through water, and extract concentrates, and drying is ground into fine powder, and the flavour of a drug fine powder with above-mentioned direct pulverizing mixes again, sieve, and add appropriate amount of auxiliary materials, make clinical adaptable preparation.
The preparation method of Chinese medicine composition pill preparation of the present invention can for:
Method for making: choose described bulk drug, be ground into fine powder, cross the 70-90 mesh sieve, mixing; 90-110 weight portion honey is in the time of 116-118 ℃, and refining density is 1.37, promptly gets refined honey; Per 100 weight portion powder add the water of refined honey 35-55 weight portion and 5-20 weight portion, general ball, and 60-80 ℃ of drying, promptly.
Pharmaceutical composition method of quality control of the present invention comprises following discrimination method and/or assay: differentiate:
A. get the preparation of quite described composition material medicine 11-13g, the 20ml that adds diethyl ether, sonicated 10-25 minute, filter, filtrate is concentrated into 1ml, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and sonicated 10-25 minute, filter, filtrate is concentrated into 1ml, makes control medicinal material solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with 8-12:1-2 sherwood oil (60～90 ℃)-ethyl acetate, launch, take out, dry, put under the ultraviolet lamp and inspect; In the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show identical light blue white fluorescent spot;
B. get the preparation of quite described composition material medicine 3.5-4.5g, the 35ml that adds diethyl ether, ultrasonic Extraction 20-40 minute, filter, filtrate volatilizes, and the 2ml that adds diethyl ether makes dissolving, as need testing solution; Get glutinous rehmannia control medicinal material 1.0g again, add the 20ml ether, ultrasonic Extraction 20-40 minute, filter, filtrate volatilizes, and the control medicinal material solution that every 1ml contains 1.0g is made in the dissolving that adds diethyl ether; According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with lower floor's solution of 7-11:1-3:1-2 chloroform-methanol-ammoniacal liquor, launch, take out, dry; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
C. get the preparation of quite described composition material medicine 1.5-2.5g, porphyrize, 20ml adds diethyl ether, sonicated 15-25 minute, filter, discard ether, residue is put water-bath Back stroke ether to the greatest extent, adds ethyl acetate 30ml, reflux 0.5-2 hour, take out, put coldly, filter, the dregs of a decoction volatilize ethyl acetate, add methyl alcohol 20ml, sonicated 10-25 minute, filter, filtrate evaporate to dryness, residue add water 10ml makes dissolving, add 3 of strong ammonia solutions again, filter, filtrate adds 3 of hydrochloric acid, and is centrifugal, abandoning supernatant, precipitation adds methyl alcohol 2ml makes dissolving, filters, and filtrate is as test sample; Other gets the scutelloside reference substance, adds methyl alcohol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with 4-7:2-5:1-2:1-2 ethyl acetate-butanone-formic acid-water, launch, take out, to dry, spray is with 1% ferric trichloride ethanolic solution; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
Assay:
According to high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; The 8-12:85-95 acetonitrile-water is a moving phase; The detection wavelength is 230nm; The preparation of reference substance solution: precision takes by weighing Paeoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, promptly; The preparation of need testing solution: get the preparation of quite described composition material medicine 3-4.5g, put in the tool plug conical flask, the accurate methyl alcohol 50ml that adds, close plug claims to decide weight, sonicated 25-40 minute, take out, put coldly, claim to decide weight again, supply the weight that subtracts mistake with methyl alcohol, filter, precision is measured subsequent filtrate 10ml, puts in the 50ml volumetric flask and is diluted to scale with methyl alcohol, shake up, promptly; Determination method: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject liquid chromatograph, measure, promptly.
Pharmaceutical composition method of quality control of the present invention is preferably as follows discrimination method and/or assay:
Differentiate:
A. get the preparation of quite described composition material medicine 11-13g, the 20ml that adds diethyl ether, sonicated 15 minutes filters, and filtrate is concentrated into 1ml, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and sonicated 15 minutes filters, and filtrate is concentrated into 1ml, makes control medicinal material solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with 9:1 sherwood oil (60～90 ℃)-ethyl acetate, launch, take out, dry, put under the 365nm ultraviolet lamp and inspect; In the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show identical light blue white fluorescent spot;
B. get the preparation of quite described composition material medicine 3.5-4.5g, the 35ml that adds diethyl ether, ultrasonic Extraction 30 minutes filters, and filtrate volatilizes, and the 2ml that adds diethyl ether makes dissolving, as need testing solution; Get glutinous rehmannia control medicinal material 1.0g again, add the 20ml ether, ultrasonic Extraction 30 minutes filters, and filtrate volatilizes, and the control medicinal material solution that every 1ml contains 1.0g is made in the dissolving that adds diethyl ether; According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with lower floor's solution of 8:2:1 chloroform-methanol-ammoniacal liquor, launch, take out, dry; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
C. get the preparation of quite described composition material medicine 1.5-2.5g, porphyrize, 20ml adds diethyl ether, sonicated 20 minutes filters, and discards ether, residue is put water-bath Back stroke ether to the greatest extent, adds ethyl acetate 30ml, reflux 1 hour, take out, put coldly, filter, the dregs of a decoction volatilize ethyl acetate, add methyl alcohol 20ml, sonicated 20 minutes, filter, filtrate evaporate to dryness, residue add water 10ml makes dissolving, add 3 of strong ammonia solutions again, filter, filtrate adds 3 of hydrochloric acid, and is centrifugal, abandoning supernatant, precipitation adds methyl alcohol 2ml makes dissolving, filters, and filtrate is as test sample; Other gets the scutelloside reference substance, adds methyl alcohol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with 5:3:1:1 ethyl acetate-butanone-formic acid-water, launch, take out, to dry, spray is with 1% ferric trichloride ethanolic solution; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
Assay:
According to high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; The 10:90 acetonitrile-water is a moving phase; The detection wavelength is 230nm; The preparation of reference substance solution: precision takes by weighing Paeoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, promptly; The preparation of need testing solution: get the preparation of quite described composition material medicine 3-4.5g, put in the tool plug conical flask, the accurate methyl alcohol 50ml that adds, close plug claims to decide weight, power 250W, frequency 40KHz sonicated 30 minutes is taken out, and puts cold, claim again to decide weight, supply the weight that subtracts mistake, filter with methyl alcohol, precision is measured subsequent filtrate 10ml, put in the 50ml volumetric flask and be diluted to scale, shake up, promptly with methyl alcohol; Determination method: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject liquid chromatograph, measure, promptly.
The present composition has good drug effect, compares the easypro sheet of existing preparation climacteric and shows good drug effect.Be used for women's climacteric syndrome clinically, the paramenia that the deficiency of liver-yin and kidney-yin causes, the hectic fever hidrosis, insomnia forgetfulness, dysphoria, dizziness and tinnitus, dry throat and mouth, aching and soreness in limb, disease curative effects such as arthralgia are clear and definite.
The method of quality control of Chinese medicine composition provided by the present invention, be by obtaining behind the creative experiment sieving of big measuring, pass through screening in the discrimination method to sample treatment, the selection of developping agent, make and differentiate that specificity is fine, and method is economic and practical, the result is quick, and can both use different thin layer plates.Pass through screening in the content assaying method to the test sample disposal route, the selection of developping agent, make content assaying method effectivelyly to carry out quality control, and will compare more stable that product that additive method measures shows on pharmacological effect with the product that this method is measured to product.
Following experimental example and embodiment are used to further specify but are not limited to the present invention.
Experimental example 1 test of pesticide effectiveness
Experiment medicine: medicine 1 (being prepared into pill) by embodiment 1 method
The fruit of glossy privet (wine is processed) 40g raspberry 30g seed of Chinese dodder 30g
The fleece-flower root (black soya bean wine is processed) 30g root bark of Chinese wolf-berry 30g adenophora tetraphylla 30g
The tuber of dwarf lilyturf 20g root of large-flowered skullcap 30g glutinous rehmannia 30g
The red spoon of root of herbaceous peony 60g 30g Radix Angelicae Sinensis 30g
Mother-of-pearl 60g radix cynanchi atrati 40g;
Medicine 2 (being prepared into pill) by embodiment 2 methods
The fruit of glossy privet (wine is processed) 40g raspberry 30g seed of Chinese dodder 30g
The fleece-flower root (black soya bean wine is processed) 30g root bark of Chinese wolf-berry 30g adenophora tetraphylla 30g
The tuber of dwarf lilyturf 20g root of large-flowered skullcap 30g glutinous rehmannia 30g
The red spoon of root of herbaceous peony 60g 30g Radix Angelicae Sinensis 30g
Mother-of-pearl 60g radix cynanchi atrati 40g wind-weed 30g
Tortoise plastron 15g reticulate millettia 50g fruit of Chinese wolfberry 20g;
Medicine 3 (being prepared into pill) by embodiment 6 methods
The fruit of glossy privet (wine is processed) 30g raspberry 20g seed of Chinese dodder 20g
The fruit of Chinese wolfberry 20g fleece-flower root (black soya bean wine is processed) 20g
Tortoise plastron 15g root bark of Chinese wolf-berry 30g adenophora tetraphylla 30g
The 20g spina date seed tuber of dwarf lilyturf (stir-fry) 10g root of large-flowered skullcap 30g
The red spoon of glutinous rehmannia 30g root of herbaceous peony 60g 30g
Radix Angelicae Sinensis 20g reticulate millettia 60g mother-of-pearl 60g
Stem of noble dendrobium 30g chrysanthemum 30g eclipta 40g
Mulberry leaf 20g radix cynanchi atrati 30g wind-weed 30g
The commercially available climacteric of the positive control medicine sheet that relaxes
(1) nourishing liver and kidney effect:
Get the Wistar big white mouse and be divided into totally 6 groups of normal group, deficiency of liver-yin and kidney-yin group, 1,2,3 groups of deficiency of liver-yin and kidney-yin drug therapies of the present invention and positive controls at random.10 of normal group, 16 of deficiency of liver-yin and kidney-yin groups, medicine group of the present invention and positive controls, 15 every group.Deficiency of liver-yin and kidney-yin group, medicine group of the present invention and positive controls are in experiment the 1st day and later per 3 days subcutaneous injection of carbon tetrachloride peanut oil (50%) 0.3ml/100g body weight, and deficiency of liver-yin and kidney-yin group gavages the deficiency of liver-yin and kidney-yin in experiment and equal moulding medicine (reserpine 0.015mg the 1st day every day, thyroxine 1mg/100g body weight), normal group irritates stomach for equivalent physiological saline, 21 days finish, medicine group of the present invention and the experiment of positive drug control group gavaged medicine of the present invention and positive control medicine 0.5g/100g body weight, totally 20 days in second day.Six groups are all carried out ecological observation, finish after 21 days, cut open the belly, and heart extracting blood, and get main internal organ and do histopathologic examination.
1, serum total cholesterol, serum triglyceride, serum high-density LP cholesteryl ester adopt homemade enzyme rapid test method, enzyme process, sodium phosphotungstate magnesium micromethod respectively.The result is as follows:
| Group | The example number | T-CHOL (mg/dl) | Triglyceride (mg/dl) | HDL-C (mg/dl) |
| Normal group | 10 | 82.64±10.01 | 63.272±13.56 | 55.174±8.341 |
| Deficiency of liver-yin and kidney-yin group | 16 | 100.19±20.57 | 78.90±18.66 | 51.833±16.578 |
| Medicine 1 of the present invention | 15? | 68.57±27.39△△ ** | 53.89±10.34△△ ** | 65.31±16.326△? |
| Medicine 2 of the present invention | 15? | 65.14±15.32△△ ** | 51.56±15.82△△ ** | 68.74±15.589△△? * |
| Medicine 3 of the present invention | 15? | 73.02±17.13△△ * | 56.73±13.35△△? * | 63.16±14.836△? |
| Positive control | 15? | 79.26±12.35△△ | 60.43±21.38△△? | 58.28±26.973? |
Compare △ △ P＜0.01, △ P＜0.05 with deficiency of liver-yin and kidney-yin group; Compare with the positive drug control group
*P＜0.01,
*P＜0.05
The result shows: medicine of the present invention and positive controls medicine have remarkable reduction effect to T-CHOL, glycerate content in the serum of deficiency of liver-yin and kidney-yin rat, and HDL-C content is had raising.Relatively there were significant differences to reducing T-CHOL and glyceric acid fat content and increasing high density lipoprotein cholesterol level for medicine of the present invention and positive controls medicine, better effects if.And between the medicine of the present invention, the effect of medicine 2 is better than medicine 1, and the effect of medicine 1 is better than medicine 3, but respectively organizes there was no significant difference.
2, serum lipid peroxide employing method is gone into Mu Shi thiobarbituricacid determination method.The results are shown in following table:
| Group | The example number | Lipid peroxide content |
| Normal group | 10 | 5.68±0.259 |
| Deficiency of liver-yin and kidney-yin group | 16 | 6.521±1.12 |
| Medicine 1 | 15 | 4.237±0.86△△ * |
| Medicine 2 | 15 | 4.125±0.47△△ * |
| Medicine 3 | 15 | 4.448±0.35△△ * |
| The positive control medicine | 15 | 4.834±0.67△△ |
Compare △ △ P＜0.01 with deficiency of liver-yin and kidney-yin group; Compare with the positive drug control group
*P＜0.05 result shows: medicine group of the present invention and positive drug control group and deficiency of liver-yin and kidney-yin group comparison serum peroxyester matter content have utmost point conspicuousness to reduce, medicine group of the present invention and positive controls relatively have the conspicuousness influence, there is not significant difference between of the present invention group of medicine, but the effect of medicine 2 is better than medicine 1, and the effect of medicine 1 is better than medicine 3.
3, liver cholesterol content adopts to cut open the belly and gets 2 livers, wear into homogenate after, mix with chloroform one methyl alcohol (1:1) and to extract the enzymatic assays cholesterol.The results are shown in following table:
| Group | The example number | Liver sterol content (mg/dl) |
| Normal group | 10 | 86.48±30.40 |
| Deficiency of liver-yin and kidney-yin group | 16 | 162.0±31.64 |
| Medicine 1 | 15 | 98.7±24.83△△ * |
| Medicine 2 | 15 | 93.6±24.83△△ * |
| Medicine 3 | 15 | 105.04±24.83△ |
| The positive control medicine | 15 | 124.04±24.83△ |
Compare △ △ P＜0.01, △ P＜0.05 with deficiency of liver-yin and kidney-yin group; Compare * P＜0.05 with the positive drug control group
The result shows: medicine group of the present invention and positive drug control group and deficiency of liver-yin and kidney-yin group comparison liver cholesterol content have conspicuousness to reduce, medicine group of the present invention and positive controls relatively have the conspicuousness influence, there is not significant difference between of the present invention group of medicine, but the effect of medicine 2 is better than medicine 1, and the effect of medicine 1 is better than medicine 3.
(2) tranquilizing effect:
Get 50 of Kunming mouses, body weight 18-22g, the male and female dual-purpose is divided into 5 groups at random, 10 every group.Physiological saline control group (negative control group): give physiological saline 0.2ml/10g and irritate stomach, every day 1 time, totally 3 days.Medicine group of the present invention and positive drug control group (medicine 1, medicine 2, medicine 3, positive control medicine): get the drug medication solution of the present invention and the positive control medicine solution 0.2ml/10g that prepare and irritate stomach, every day 1 time, totally 3 days.Each is organized last and irritates 1h behind the stomach, after mouse is put into the spontaneous activity instrument and adapts to 3 minutes, begins to measure the spontaneous activity number of times and sleep surpasses 2 hours the length of one's sleep.The results are shown in following table:
| Group | Dosage (g/kg) | The spontaneous activity number of times | The length of one's sleep (min) |
| Negative control group | ? | 169.7±63.1 | 40.0±15.5 |
| Medicine 1 | 1.5 | 113.7±61.2△△ * | 72.4±23.3△△ |
| Medicine 2 | 1.5 | 102.6±57.7△△ * | 77.8±25.0△△ * |
| Medicine 3 | 1.5 | 121.8±68.5△△ | 68.5±23.9△△ |
| The positive control medicine | 1.5 | 134.5±64.3△ | 63.8±19.7△△ |
Compare △ △ P＜0.01, △ P＜0.05 with negative control group; Compare with the positive drug control group
*P＜0.05
The result shows: medicine group of the present invention and positive drug control group and negative control group comparison tranquilizing effect have conspicuousness to improve, medicine group of the present invention and positive controls relatively have significant difference, tranquilizing effect is that the effect of medicine 2 is better than medicine 1 between of the present invention group of medicine, and the effect of medicine 1 is better than medicine 3.
(3) effect of nourishing blood:
Get 90 of body weight 18～21g mouse, female, evenly be divided into 9 groups at random, wherein make the virtual model of losing blood for 8 groups.9 treated animals afterbody before experiment is got blood, survey Hb earlier, the RBC level, 8 groups of difference of modeling type afterbody bloodletting 0.5ml, animal is lost blood, in lose blood back 24h again afterbody get blood and survey Hb, RBC observes the degree that causes the deficiency of blood, gavage big then respectively, low dose of pharmaceutical preparation 5g/kg of the present invention, 1.7g/kg, be equivalent to 30 times of clinical consumption respectively, 10 times), positive control medicine (2.5g/kg, the dosage that is equivalent to be grown up 30 times) and physiological saline (20ml/kg), the blank group gavages the physiological saline with volume, administration every day 1 time, successive administration 7 days is in last 1 administration 2h, afterbody is got blood and is surveyed Hb again, RBC the results are shown in following table:
*Expression and model group is than P＜0.05,
*Expression and model group be than P＜0.01, △ represent with the positive control medicine than P＜0.05
The result shows: medicine of the present invention and positive control medicine all can significantly improve Hb, RBC level.The large and small dosage of medicine of the present invention all has remarkable result, medicine of the present invention and positive control medicine comparative effectiveness have conspicuousness to improve, illustrate that the invention medicine has the good effect of nourishing blood, there is not significant difference between medicine of the present invention, but the effect of its Chinese traditional medicine 2 is better than medicine 1, and the effect of medicine 1 is better than medicine 3.
(4) vein relaxing effect:
Get 36 of rabbit, be divided into 6 groups at random, the auris dextra depilation, first group is the blank group; Second group only gives the wax thermotherapy at every rat right hind leg; Third and fourth, five groups give medicine 1, medicine 2, medicine 3 respectively, add the wax thermotherapy; The 6th group gives the positive control medicine, adds the wax thermotherapy.Every day 1 time, continuous 7 days.After 7 days auris dextra was placed-10 ℃ of ethanol freezing 2 minutes, and under anatomical lens, measured fixed point arteriole diameter, freeze postfixed point arteriole diameter before calculating is frozen and change.The results are shown in following table:
| Group | The swelling percent |
| The blank group | 46.7±10.3 |
| Wax thermotherapy group | 33.1±16.0 |
| Medicine 1 | 16.8±8.2* |
| Medicine 2 | 15.2±10.1* |
| Medicine 3 | 19.2±6.4* |
| Positive control medicine+wax thermotherapy group | 23.2±5.8 |
Annotate:
*With wax thermotherapy group than P＜0.05
The result shows: medicine of the present invention adds wax thermotherapy group and wax thermotherapy group relatively to be prevented arteriole due to freezing to shrink to have conspicuousness to improve, and the vein relaxing effect of medicine of the present invention is higher than the positive control medicine.
Experimental example 2 is differentiated screening experiment
1, the thin layer of Radix Angelicae Sinensis is differentiated
1. the investigation of need testing solution extraction time
Get bolus of drug 15g of the present invention, grind, the 20ml that adds diethyl ether, sonicated filters, and filtrate is concentrated into 1ml, as need testing solution.Other gets Radix Angelicae Sinensis control medicinal material 1g, and the 10ml that adds diethyl ether shines medicinal material solution in pairs with legal system.Test according to thin-layered chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with sherwood oil (60～90 ℃)-ethyl acetate (9:1) is developping agent, launch, take out, dry, put under the ultraviolet lamp (365nm) and inspect.Relatively extract different time need testing solution and the reference substance solution color developing effect on thin layer plate, the results are shown in following table:
| Ultrasonic time | 5min | 10min | 15min | 20min |
| Color developing effect | Test sample be can't see colour developing | Test sample is glimmering | Test sample and contrast | Test sample and contrast |
| ? | The fluorescence spot, the colour developing of reference substance fluorescence spot is fuzzyyer | The colour developing of hot spot point is fuzzyyer | It is clear that product fluorescence spot all develops the color | It is clear that product fluorescence spot all develops the color |
As can be seen from the above table, when extraction time be 15min when above need testing solution and reference substance solution on thin layer plate, develop the color clearly, reached requirement of experiment.So consider from saving experimental period, select ultrasonic Extraction 15min.
2. the selection of developping agent
According to the preparation method of need testing solution described in 1. and reference substance solution, preparation need testing solution and reference substance solution.According to thin-layered chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000) test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, launch with different developping agents, take out, dry, put under the ultraviolet lamp (365nm) and inspect.Relatively use different developping agents and launch, need testing solution and the reference substance solution expansion effect on thin layer plate the results are shown in following table:
| Developping agent | Sherwood oil (60～90 ℃)-ethyl acetate (7:3) | Sherwood oil (60～90 ℃)-ethyl acetate (8:2) | Sherwood oil (60～90 ℃)-ethyl acetate (9:1) | Normal hexane-ethyl acetate (7: 3) | Normal hexane-ethyl acetate (8: 2) | Normal hexane-ethyl acetate (9: 1) |
| Launch effect | Separate unclearly, launch weak effect. | Separate unclearly, launch weak effect. | Separate clearly, launch effective. | Separate unclearly, launch weak effect, interference is arranged. | Separate unclearly, interference is arranged. | Separate unclearly, launch weak effect, interference is arranged. |
From above experimental result as can be seen, need testing solution and reference substance solution were launched effectively on thin layer plate when developping agent was a sherwood oil (60～90 ℃)-ethyl acetate (9:1), occurred separating unclear, and it is bad to launch effect, interference etc. is arranged, meet requirement of experiment.
3. negative control test
Get the negative sample that lacks Ligusticum wallichii, prepare negative sample solution, launch the back and on control medicinal material solution correspondence position, corresponding spot do not occur, illustrate that selected identification experiment specificity is strong according to need testing solution preparation method in the above-mentioned discrimination method.
2, the thin layer of glutinous rehmannia is differentiated
1. the examination of need testing solution extraction time
Get bolus of drug 5g of the present invention, porphyrize, the 35ml that adds diethyl ether, ultrasonic Extraction filters, and filtrate volatilizes, and the 2ml that adds diethyl ether makes dissolving, as need testing solution.Get glutinous rehmannia control medicinal material 1.0g again, make the control medicinal material solution that every 1ml contains 1.0g with method.According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with lower floor's solution of chloroform-methanol-ammoniacal liquor (8:2:1), launch, take out, dry.Relatively extract different time need testing solution and the reference substance solution color developing effect on thin layer plate, the results are shown in following table:
| Ultrasonic time | 15min | 25min | 35min | 50min |
| Color developing effect | Test sample be can't see the spot of colour developing, and the colour developing of reference substance fluorescence spot is fuzzyyer | The colour developing of test sample spot is fuzzyyer | It is clear that test sample and reference substance spot all develop the color | It is clear that test sample and reference substance spot all develop the color |
As can be seen from the above table, when extraction time be 35min when above need testing solution and reference substance solution on thin layer plate, develop the color clearly, reached requirement of experiment.
2. the selection of developping agent
Drawing need testing solution and each 5 μ l of reference substance solution of method for preparing, put respectively on same silica gel g thin-layer plate, is developping agent with lower floor's solution of chloroform-methanol-water and the different proportionings of chloroform-methanol-ammoniacal liquor, launches, and taking-up is dried.Relatively extract different time need testing solution and the reference substance solution expansion effect on thin layer plate, the results are shown in following table:
| Developping agent | Chloroform-methanol-ammoniacal liquor (7:3:1) | Chloroform-methanol-ammoniacal liquor (8:2:1) | Chloroform-methanol-water ammonia (9:1:1) | Chloroform-methanol-water (8:2:1) | Chloroform-methanol-water (13:6:1) | Chloroform-methanol-water (16:6:1) |
| Launch effect | Launch weak effect, separate unclear | Separate clearly, launch effective | Launch weak effect, the tail of taking off is arranged | Interference is arranged after the expansion | Launch weak effect, interference is arranged | Launch weak effect, interference is arranged |
As can be seen from the above table, be developping agent with chloroform-methanol-ammoniacal liquor (8:2:1), need testing solution and reference substance solution each spot developping agent on thin layer plate is effective, tail, inferior separating effect, interference etc. do not occur taking off.
3. negative control test
Get the negative sample that lacks glutinous rehmannia, prepare negative sample solution, launch the back and on control medicinal material solution correspondence position, corresponding spot do not occur, illustrate that selected identification experiment specificity is strong according to need testing solution preparation method in the above-mentioned discrimination method.
3, the thin layer of the root of large-flowered skullcap is differentiated
1. the preparation method of need testing solution
Method one, get bolus of drug 2g of the present invention, porphyrize, 20ml adds diethyl ether, sonicated 20 minutes filters, and discards ether, residue is put water-bath Back stroke ether to the greatest extent, adds ethyl acetate 30ml, reflux 1 hour, take out, put coldly, filter, the dregs of a decoction volatilize ethyl acetate, add methyl alcohol 20ml, sonicated 20 minutes, filter, filtrate evaporate to dryness, residue add water 10ml makes dissolving, add 3 of strong ammonia solutions again, filter, filtrate adds 3 of hydrochloric acid, and is centrifugal, supernatant discarded night, precipitation adds methyl alcohol 2ml makes dissolving, filters, and filtrate is as test sample.Method two, get bolus of drug 2g of the present invention, porphyrize adds methyl alcohol 20ml, and sonicated 20 minutes filters, and filtrate evaporate to dryness, residue add methyl alcohol 10ml makes dissolving, as need testing solution.
Other gets the scutelloside reference substance, adds methyl alcohol and makes the solution that every 1ml contains 1mg, in contrast product solution.Test according to thin-layered chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with ethyl acetate-butanone-formic acid-water (5:3:1:1) is developping agent, launch, take out, dry, spray is with 1% ferric trichloride ethanolic solution.Compare Different Extraction Method the test sample expansion and the color developing effect at molten night, the results are shown in following table:
| The preparation method | Method 1 | Method 2 |
| Launch and color developing effect | The need testing solution principal spot is analysed clearly, and is noiseless. | The need testing solution principal spot is unclear analyses, and disturbs big. |
As can be seen from the above table, employing method one preparation need testing solution after the expansion, has not only been eliminated the interference of other impurity, and more clear the analysing of principal spot colour developing, and the experiment accuracy is higher.
In method 1, compare the ultrasonic Extraction that adds diethyl ether in the different step, added the ethyl acetate refluxing extraction and added time of methyl alcohol ultrasonic Extraction, in method 2, compared the time that adds the methyl alcohol ultrasonic Extraction, the result shows that the selected experimental period of above experiment is reasonable, science, meets requirement of experiment.
3. the selection of developping agent proportioning
Draw each 5 μ l of need testing solution and reference substance solution, put respectively on same silica gel g thin-layer plate, the developping agent with the different proportionings of ethyl acetate-butanone-formic acid-water launches, and takes out, and dries, and spray is with 1% ferric trichloride ethanolic solution.Under the more different proportioning developping agents, need testing solution and the reference substance solution expansion effect on thin layer plate the results are shown in following table:
| The developping agent proportioning | 3：5：1：1? | 4：4：1：1? | 5：3：1：1? | 6：2：1：1? |
| Launch effect | Launch weak effect, the test sample principal spot separates unclear analysing. | Launch weak effect, the test sample principal spot separates unclear analysing. | Launch effectively, the test sample principal spot separates analyses clearly. | Launch weak effect, the test sample principal spot separates unclear analysing. |
As can be seen from the above table, when the proportioning of developping agent ethyl acetate-butanone-formic acid-water was 5:3:1:1, it is all good that need testing solution and reference substance solution principal spot launch effect, and test sample principal spot do not occur and separates unclear analysing, phenomenons such as interference are arranged, meet requirement of experiment.
3. negative control test
Get the negative sample that lacks the root of large-flowered skullcap, prepare negative sample solution, launch the back and on control medicinal material solution correspondence position, corresponding spot do not occur, illustrate that selected identification experiment specificity is strong according to need testing solution preparation method in the above-mentioned discrimination method.
The part thin layer that more than is Radix Angelicae Sinensis, glutinous rehmannia, the root of large-flowered skullcap in the medicine of the present invention is differentiated shaker test, and empirical tests can effectively be controlled the quality of drug combination preparation of the present invention from the qualitative detection aspect, and the quality of drug combination preparation of the present invention is improved.
Experimental example 3 assay screening experiments
Adopt the content of paeoniflorin in the high-efficient liquid phase color popularize law mensuration medicine of the present invention, to improve quality determining method of the present invention, part test the results are shown in down:
1. the preparation of need testing solution
Get bolus of drug 4g of the present invention, put in the tool plug conical flask, the accurate methyl alcohol 50ml that adds, close plug claims to decide weight, power 250W, frequency 40KHz sonicated, take out, put coldly, claim to decide weight again, supply the weight that subtracts mistake with methyl alcohol, filter, precision is measured subsequent filtrate 10ml, puts in the 50ml volumetric flask and is diluted to scale with methyl alcohol, shake up, promptly.Compared different ultrasonic times, content of paeoniflorin in the need testing solution, the result is as follows:
| Ultrasonic time | 10 minutes | 20 minutes | 30 minutes | 50 minutes |
| Paeoniflorin content (mg/g) | 1.2307 | 1.9232 | 2.5187 | 2.5517 |
As can be seen from the above table, ultrasonic Extraction can be extracted the Paeoniflorin in the medicine of the present invention fully in 30 minutes, so the preparation of need testing solution selects ultrasonic Extraction to get final product in 30 minutes.
2. the selection of moving phase
Get test sample molten night, respectively with the moving phase of acetonitrile-water with methyl alcohol-different proportionings of 0.05mol/L potassium dihydrogen phosphate, the separating effect at each peak in the need testing solution chromatogram relatively the results are shown in following table:
| Proportion of mobile phase | Acetonitrile-water (30:70) | Acetonitrile-water (20:80) | Acetonitrile-water (10:90) | Methyl alcohol-0.05mol/L potassium dihydrogen phosphate (50:55) | Methyl alcohol-0.05mol/L potassium dihydrogen phosphate (40:65) | Methyl alcohol-0.05mol/L potassium dihydrogen phosphate (30:75) |
| Chromatographic peak separating effect fruit | Inferior separating effect has interference | The inferior separating effect fruit is poor, and interference is arranged | Good separating effect, noiseless | Inferior separating effect has interference | Inferior separating effect has interference | Inferior separating effect has interference |
As can be seen from the above table, disturbing does not appear in the good separating effect at each peak in test sample chromatogram when moving phase is acetonitrile-water (10:90), main peak.
3. the methodological study of content detection
To the detection method of content that medicine of the present invention adopted, carried out related side's science of law from aspects such as linear relationship, stability, precision, reappearance, the recovery and investigated, concrete grammar and result are as follows:
Detecting instrument (room temperature detection): Agilent 1100 type High Performance Liquid Chromatography posts: (Zorbax C184.6 * 150mm, 5 μ m) producer: Agilent Techologies Anjelen Sci. ﹠ Tech. Inc (China) moving phase: acetonitrile-water (10:90) detects wavelength: 230nm flow velocity: 1.0ml/min column temperature: room temperature reference substance source: Paeoniflorin is purchased the lot number in Nat'l Pharmaceutical ﹠ Biological Products Control Institute: the 0736-9913 assay method: the accurate respectively negative controls of drawing, each 10 μ l of reference substance liquid and need testing solution, inject liquid chromatograph, measure, promptly.
(1) stability test reference substance solution respectively at preparing the back 0,2,4,6,12,24 hour, is measured in accordance with the law, and the result shows that it is basicly stable in 24 hours, the results are shown in following table:
(2) linear relationship is investigated and to be got reference substance solution (48.5 μ g/ml) and shake up, accurate respectively 2,4,6,8,10, the 12 μ l of absorption inject high performance liquid chromatograph, measure peak area, the results are shown in following table, and drawing standard curve, show that Paeoniflorin is linear between 0.097 μ g-0.582 μ g, its regression equation is:
Area＝1356.2714*Amt+7.7626(r＝0.9998)
(3) the accurate need testing solution 10 μ l that draw of precision test repeat sample introduction 5 times, try to achieve relative standard deviation＜2%, the results are shown in following table:
(4) the text method is pressed in reappearance test, gets five parts of same bolus of drug of the present invention, and every part is measured, and tries to achieve relative standard deviation＜2%, the results are shown in following table:
(5) the recovery test precision take by weighing known content bolus of drug 2.5g same of the present invention more respectively precision take by weighing Paeoniflorin reference substance 50mg, be configured to the solution of 0.5mg/ml, precision is measured 10ml, preparation method's operation by above-mentioned need testing solution, measure its content, and calculate its recovery, measurement result sees the following form:
| Tested number | Sampling amount (g) | Paeoniflorin amount mg in the sample) | Add Paeoniflorin amount (mg) | Measure Paeoniflorin amount (mg) | The recovery (%) | Average recovery rate (%) | RSD(％)? |
| 1 | 2.5023 | 6.5579 | 5.00 | 11.3209 | 95.26 | ? | ? |
| 2 | 2.6321 | 6.5212 | 5.00 | 11.1807 | 93.19 | ? | ? |
| 3 | 2.4983 | 6.5475 | 5.00 | 11.3790 | 96.63 | 95.13 | 1.3732 |
| 4 | 2.5432 | 6.6651 | 5.00 | 11.3991 | 94.68 | ? | ? |
| 5 | 2.5119 | 6.5831 | 5.00 | 11.3781 | 95.90 | ? | ? |
(6) blank test
Ratio according to drug prescription taste of traditional Chinese medicine of the present invention, press oral liquid formulations technology, preparation does not contain the negative sample of the root of herbaceous peony, the radix paeoniae rubrathe, according to need testing solution preparation method preparation and detection, negative sample solution is that the identical retention time of Paeoniflorin reference substance place does not have chromatographic peak as a result, so negative noiseless.
By above methodology examination result as can be seen, its linear relationship of the content assaying method that medicine of the present invention adopted, stability, precision, reappearance etc. are all good, can effectively control drug quality of the present invention.
Following embodiment all can realize the described effect of above-mentioned experimental example
Embodiment
Embodiment 1: pill
The fruit of glossy privet (wine is processed) 40g raspberry 30g seed of Chinese dodder 30g
The fleece-flower root (black soya bean wine is processed) 30g root bark of Chinese wolf-berry 30g adenophora tetraphylla 30g
The tuber of dwarf lilyturf 20g root of large-flowered skullcap 30g glutinous rehmannia 30g
The red spoon of root of herbaceous peony 60g 30g Radix Angelicae Sinensis 30g
Mother-of-pearl 60g radix cynanchi atrati 40g;
More than 14 flavors, be ground into fine powder, sieve (be meant whole energy by 80 mesh sieves), mixing, drug powder.Honey is in the time of 116-118 ℃, and refining density is 1.37, promptly gets refined honey; Every 100g powder adds refined honey 42g and water 8g, general ball, and low temperature (60-80 ℃) drying, promptly.
Embodiment 2: pill
The fruit of glossy privet (wine is processed) 40g raspberry 30g seed of Chinese dodder 30g
The fleece-flower root (black soya bean wine is processed) 30g root bark of Chinese wolf-berry 30g adenophora tetraphylla 30g
The tuber of dwarf lilyturf 20g glutinous rehmannia 30g root of large-flowered skullcap 30g
The red spoon of root of herbaceous peony 60g 30g Radix Angelicae Sinensis 30g
Mother-of-pearl 60g radix cynanchi atrati 40g wind-weed 30g
Tortoise plastron 15g reticulate millettia 50g fruit of Chinese wolfberry 20g;
More than 18 flavors, be ground into fine powder, sieve (be meant whole energy by 80 mesh sieves), mixing, drug powder.Honey is in the time of 116-118 ℃, and refining density is 1.37, promptly gets refined honey; Every 100g powder adds refined honey 42g and water 8.5g, general ball, and low temperature (60-80 ℃) drying, promptly.
Embodiment 3: effervescent agent
The fruit of glossy privet (wine is processed) 50g raspberry 10g seed of Chinese dodder 50g
The fruit of Chinese wolfberry 10g fleece-flower root (black soya bean wine is processed) 50g
Tortoise plastron 10g root bark of Chinese wolf-berry 50g adenophora tetraphylla 20g
The 40g spina date seed tuber of dwarf lilyturf (stir-fry) 10g root of large-flowered skullcap 60g
The red spoon of glutinous rehmannia 20g root of herbaceous peony 80g 20g
Radix Angelicae Sinensis 50g reticulate millettia 50g mother-of-pearl 80g
Stem of noble dendrobium 20g chrysanthemum 60g eclipta 30g
Mulberry leaf 20g radix cynanchi atrati 50g wind-weed 30g
More than 23 flavors, except that tortoise plastron, spina date seed, mother-of-pearl, all the other flavour of a drug add 8 times of water gagings and decoct 2 times, each 1.5 hours, filter, merging filtrate, being concentrated into relative density is 1.30 (50～55 ℃), vacuum drying is ground into fine powder, and is standby.Tortoise plastron, spina date seed, Concha Margaritifera powder are broken to more than 100 orders, sieve, mix, be divided into two equal portions with above-mentioned fine powder, an amount of low-substituted hydroxypropyl cellulose, xanthans.Add 16.1% sodium bicarbonate mixing in the portion, make alkali grain, drying; Another part adds 19.3% citric acid and 0.05% sweetener mixing, makes acid particles, and drying with two kinds of dried particle mixings, sprays into flavouring agent, and the sealing certain hour gets final product.
Embodiment 4: dripping pill
The fruit of glossy privet (wine is processed) 60g raspberry 20g seed of Chinese dodder 50g
The fleece-flower root (black soya bean wine is processed) 20g root bark of Chinese wolf-berry 60g adenophora tetraphylla 20g
The tuber of dwarf lilyturf 10g glutinous rehmannia 20g root of large-flowered skullcap 50g
The red spoon of root of herbaceous peony 90g 20g Radix Angelicae Sinensis 50g
Mother-of-pearl 50g radix cynanchi atrati 70g wind-weed 20g
Tortoise plastron 55g reticulate millettia 30g fruit of Chinese wolfberry 50g;
More than 18 the flavor, be ground into fine powder, sieve mixing, fine powder mixes with the Macrogol 4000 of an amount of fusion, 70 ℃ of insulations, and through the water dropper of a certain size caliber, constant speed splashes in the whiteruss liquid coolant, the pill that will solidify formation takes out, the flush away liquid coolant, and drying.
Embodiment 5: soft capsule
The fruit of glossy privet (wine is processed) 60g raspberry 20g seed of Chinese dodder 60g
The fleece-flower root (black soya bean wine is processed) 25g root bark of Chinese wolf-berry 60g adenophora tetraphylla 20g
The tuber of dwarf lilyturf 60g root of large-flowered skullcap 20g glutinous rehmannia 30g
The red spoon of root of herbaceous peony 80g 20g Radix Angelicae Sinensis 30g
Mother-of-pearl 90g radix cynanchi atrati 40g;
More than 14 flavors, except that tortoise plastron, spina date seed, mother-of-pearl, all the other flavour of a drug add 8 times of water gagings and decoct 2 times, each 1.5 hours, filter, merging filtrate concentrates, drying is ground into fine powder (more than 100 orders), and is standby.Tortoise plastron, spina date seed, Concha Margaritifera powder are broken to more than 100 orders, sieve, mix,, be pressed into soft capsule evenly mixed with an amount of vegetable oil and beeswax heating with above-mentioned fine powder.Soft capsule shell is prepared from by a certain percentage by gelatin, glycerine, water.
Embodiment 6:
The fruit of glossy privet (wine is processed) 30g raspberry 20g seed of Chinese dodder 20g
The fruit of Chinese wolfberry 20g fleece-flower root (black soya bean wine is processed) 20g
Tortoise plastron 15g root bark of Chinese wolf-berry 30g adenophora tetraphylla 30g
The 20g spina date seed tuber of dwarf lilyturf (stir-fry) 10g root of large-flowered skullcap 30g
The red spoon of glutinous rehmannia 30g root of herbaceous peony 60g 30g
Radix Angelicae Sinensis 20g reticulate millettia 60g mother-of-pearl 60g
Stem of noble dendrobium 30g chrysanthemum 30g eclipta 40g
Mulberry leaf 20g radix cynanchi atrati 30g wind-weed 30g
Method for making: above 23 flavors are ground into fine powder, sieve (being meant that whole energy are by 80 mesh sieves), mixing.Honey is in the time of 116-118 ℃, and refining density is 1.37, promptly gets refined honey; Every 100g powder adds refined honey 42g and water 8.4g, general ball, and (60-80 ℃) drying is made 8700;
Differentiate:
(1) get this product, put microscopically and observe: the parenchymal tissue taupe brown is to dark brown, and the many shrinkages of cell include brown nuclear shape thing; Nonglandular hair mostly is 3 cells, and the middle part cell is longer, and obvious verruca is arranged, the anxious point of apical cell and lacking; In the fiber surface similar round cell, contain siliceous of tiny circle, be arranged in rows; Bordered pit vessel is big; The fibrous bundle peripheral cell contains prism of calcium oxalate and forms crystal fiber; Plant skin palisade cells 2 row, the outer row of interior row are long; It is faint yellow to plant the skin lithocyte, the wavy bending of wall, and cell contains brown thing; The pale brown look of endotesta cell, surface sight rectangle or class are square, and the anticline beaded thickens; Fiber is faint yellow, fusiformis, and wall thickness, the hole ditch is thin; Fiber often is connected with the ray cell; Parenchyma cell contains calcium oxalate sand crystal; Nonglandular hair is unicellular, wall thickness, and lignify, the back vestiges that come off are like the lithocyte shape;
(2) get this product 1g, grind, add watery hydrochloric acid 20ml, promptly produce a large amount of bubbles, filter, filtrate shows the various identifications of calcium salt;
(3) get this product 15g, grind, the 20ml that adds diethyl ether, sonicated 15 minutes filters, and filtrate is concentrated into 1ml, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and sonicated 15 minutes filters, and filtrate is concentrated into 1ml, makes control medicinal material solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with sherwood oil (60～90 ℃)-ethyl acetate (9:1), launch, take out, dry, put under the ultraviolet lamp (365nm) and inspect; In the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show identical light blue white fluorescent spot;
(4) get this product 5g, porphyrize, the 35ml that adds diethyl ether, ultrasonic Extraction 30 minutes filters, and filtrate volatilizes, and the 2ml that adds diethyl ether makes dissolving, as need testing solution; Get glutinous rehmannia control medicinal material 1.0g again,
Same methodMake the control medicinal material solution that every 1ml contains 1.0g; According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with lower floor's solution of chloroform-methanol-ammoniacal liquor (8:2:1), launch, take out, dry; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
(5) get this product 2g, porphyrize, the 20ml that adds diethyl ether, sonicated 20 minutes filters, discard ether, residue is put water-bath Back stroke ether to the greatest extent, adds ethyl acetate 30ml, and reflux 1 hour is taken out, put coldly, filter, the dregs of a decoction volatilize ethyl acetate, add methyl alcohol 20ml, sonicated 20 minutes filters, and filtrate evaporate to dryness, residue add water 10ml makes dissolving, add 3 of strong ammonia solutions again, filter, filtrate adds 3 of hydrochloric acid, and is centrifugal, abandoning supernatant, precipitation adds methyl alcohol 2ml makes dissolving, filters, and filtrate is as test sample; Other gets the scutelloside reference substance, adds methyl alcohol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with ethyl acetate-butanone-formic acid-water (5:3:1:1), launch, take out, to dry, spray is with 1% ferric trichloride ethanolic solution; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
Assay:
According to high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; Acetonitrile-water (10:90) is a moving phase; The detection wavelength is 230nm; The preparation of reference substance solution: precision takes by weighing Paeoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, and promptly gets (containing Paeoniflorin 50 μ g among every 1ml); The preparation of need testing solution: get the content under this product content uniformity item, porphyrize, 4g decided in accurate title, put in the tool plug conical flask accurate methyl alcohol 50ml, the close plug of adding, claim to decide weight, sonicated (power 250W, frequency 40KHz) 30 minutes, take out, put coldly, claim to decide weight again, supply the weight that subtracts mistake with methyl alcohol, filter, precision is measured subsequent filtrate 10ml, put in the 50ml volumetric flask and be diluted to scale, shake up, promptly with methyl alcohol; Determination method: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject liquid chromatograph, measure, promptly; This product contains Paeoniflorin (C for every bag
23H
28O
11), must not be less than 6.0mg.
Function cures mainly: nourishing liver and kidney, and tranquilizing and allaying excitement, blood nourishing acupuncture-stimulating.Be used for women's climacteric syndrome, the paramenia that the deficiency of liver-yin and kidney-yin causes, hectic fever hidrosis, insomnia forgetfulness, dysphoria, dizziness and tinnitus, dry throat and mouth, aching and soreness in limb, diseases such as arthralgia.
Claims (7)
1. pharmaceutical composition for the treatment of women's climacteric syndrome is characterized in that the bulk drug of this pharmaceutical composition consists of:
Wine is processed fruit of glossy privet 10-60 weight portion raspberry 10-50 weight portion
Seed of Chinese dodder 10-50 weight portion black soya bean wine is processed fleece-flower root 10-50 weight portion
Root bark of Chinese wolf-berry 10-60 weight portion adenophora tetraphylla 10-60 weight portion
The tuber of dwarf lilyturf 10-50 weight portion root of large-flowered skullcap 10-60 weight portion
Glutinous rehmannia 10-60 weight portion root of herbaceous peony 20-100 weight portion
Radix paeoniae rubrathe 10-60 weight portion Radix Angelicae Sinensis 10-50 weight portion
Mother-of-pearl 20-100 weight portion radix cynanchi atrati 10-60 weight portion.
2. pharmaceutical composition as claimed in claim 1 is characterized in that the bulk drug in this pharmaceutical composition consists of:
Wine is processed the fruit of glossy privet 40 weight portion raspberries 30 weight portions
The seed of Chinese dodder 30 weight portion black soya bean wines are processed the fleece-flower root 30 weight portions
The root bark of Chinese wolf-berry 30 weight portion adenophora tetraphyllas 30 weight portions
The tuber of dwarf lilyturf the 20 weight portion roots of large-flowered skullcap, 30 weight portions
The glutinous rehmannia 30 weight portion root of herbaceous peonys 60 weight portions
The radix paeoniae rubrathe 30 weight portion Radix Angelicae Sinensis 30 weight portions
Mother-of-pearl 60 weight portion radix cynanchi atratis 40 weight portions.
3. pharmaceutical composition as claimed in claim 1 is characterized in that the bulk drug of this pharmaceutical composition consists of:
Wine is processed fruit of glossy privet 10-60 weight portion raspberry 10-50 weight portion
Seed of Chinese dodder 10-50 weight portion black soya bean wine is processed fleece-flower root 10-50 weight portion
Root bark of Chinese wolf-berry 10-60 weight portion adenophora tetraphylla 10-60 weight portion
The tuber of dwarf lilyturf 10-50 weight portion root of large-flowered skullcap 10-60 weight portion
Glutinous rehmannia 10-60 weight portion root of herbaceous peony 20-100 weight portion
Radix paeoniae rubrathe 10-60 weight portion Radix Angelicae Sinensis 10-50 weight portion
Mother-of-pearl 20-100 weight portion radix cynanchi atrati 10-60 weight portion
Wind-weed 10-60 weight portion tortoise plastron 10-60 weight portion
Reticulate millettia 20-100 weight portion fruit of Chinese wolfberry 10-50 weight portion.
4. pharmaceutical composition as claimed in claim 3 is characterized in that the bulk drug of this pharmaceutical composition consists of:
Wine is processed the fruit of glossy privet 40 weight portion raspberries 30 weight portions
The seed of Chinese dodder 30 weight portion black soya bean wines are processed the fleece-flower root 30 weight portions
The root bark of Chinese wolf-berry 30 weight portion adenophora tetraphyllas 30 weight portions
The tuber of dwarf lilyturf the 20 weight portion roots of large-flowered skullcap, 30 weight portions
The glutinous rehmannia 30 weight portion root of herbaceous peonys 60 weight portions
The radix paeoniae rubrathe 30 weight portion Radix Angelicae Sinensis 30 weight portions
Mother-of-pearl 60 weight portion radix cynanchi atratis 40 weight portions
The wind-weed 30 weight portion tortoise plastrons 15 weight portions
The reticulate millettia 50 weight portion fruits of Chinese wolfberry 20 weight portions;
5. as the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that this preparation of drug combination method is:
Choose described bulk drug, be ground into fine powder, cross the 70-90 mesh sieve, mixing; 90-110 weight portion honey is in the time of 116-118 ℃, and refining density is 1.37, promptly gets refined honey; Per 100 weight portion powder add the water of refined honey 35-55 weight portion and 5-20 weight portion, general ball, and 60-80 ℃ of drying, promptly.
6. as the detection method of the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that this detection method comprises following discrimination method and/or content assaying method:
Differentiate:
A. get preparation and be equivalent to described composition material medicine 11-13g, the 20ml that adds diethyl ether, sonicated 10-25 minute, filter, filtrate is concentrated into 1ml, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and sonicated 10-25 minute, filter, filtrate is concentrated into 1ml, makes control medicinal material solution; According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 8-12: 1-2 sherwood oil-ethyl acetate is a developping agent, and sherwood oil is 60～90 ℃, launches, and takes out, and dries, and puts under the ultraviolet lamp and inspects; In the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show identical light blue white fluorescent spot;
B. get preparation and be equivalent to described composition material medicine 3.5-4.5g, the 35ml that adds diethyl ether, ultrasonic Extraction 20-40 minute, filter, filtrate volatilizes, and the 2ml that adds diethyl ether makes dissolving, as need testing solution; Get glutinous rehmannia control medicinal material 1.0g again, add the 20ml ether, ultrasonic Extraction 20-40 minute, filter, filtrate volatilizes, and the control medicinal material solution that every 1ml contains 1.0g is made in the dissolving that adds diethyl ether; According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 7-11: 1-3: lower floor's solution of 1-2 chloroform-methanol-ammoniacal liquor is developping agent, launches, and takes out, and dries; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
C. get preparation and be equivalent to described composition material medicine 1.5-2.5g, porphyrize, 20ml adds diethyl ether, sonicated 15-25 minute, filter, discard ether, residue is put water-bath Back stroke ether to the greatest extent, adds ethyl acetate 30ml, reflux 0.5-2 hour, take out, put coldly, filter, the dregs of a decoction volatilize ethyl acetate, add methyl alcohol 20ml, sonicated 10-25 minute, filter, filtrate evaporate to dryness, residue add water 10ml makes dissolving, add 3 of strong ammonia solutions again, filter, filtrate adds 3 of hydrochloric acid, and is centrifugal, abandoning supernatant, precipitation adds methyl alcohol 2ml makes dissolving, filters, and filtrate is as test sample; Other gets the scutelloside reference substance, adds methyl alcohol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 4-7: 2-5: 1-2: 1-2 ethyl acetate-butanone-formic acid-water is developping agent, launches, and takes out, and dries, and spray is with 1% ferric trichloride ethanolic solution; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
Assay:
According to high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; 8-12: the 85-95 acetonitrile-water is a moving phase; The detection wavelength is 230nm; The preparation of reference substance solution: precision takes by weighing Paeoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, promptly; The preparation of need testing solution: get the preparation of quite described composition material medicine 3-4.5g, put in the tool plug conical flask, the accurate methyl alcohol 50ml that adds, close plug claims to decide weight, sonicated 25-40 minute, take out, put coldly, claim to decide weight again, supply the weight that subtracts mistake with methyl alcohol, filter, precision is measured subsequent filtrate 10ml, puts in the 50ml volumetric flask and is diluted to scale with methyl alcohol, shake up, promptly; Determination method: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject liquid chromatograph, measure, promptly.
8. the method for quality control of pharmaceutical composition as claimed in claim 7 is characterized in that this method of quality control comprises following discrimination method and/or content assaying method:
Differentiate:
A. get preparation and be equivalent to described composition material medicine 11-13g, the 20ml that adds diethyl ether, sonicated 15 minutes filters, and filtrate is concentrated into 1ml, as need testing solution; Other gets Radix Angelicae Sinensis control medicinal material 1g, the 10ml that adds diethyl ether, and sonicated 15 minutes filters, and filtrate is concentrated into 1ml, makes control medicinal material solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with 9: 1 sherwood oil-ethyl acetates, sherwood oil is 60～90 ℃, launches, and takes out, and dries, and puts under the 365nm ultraviolet lamp and inspects; In the test sample chromatogram, with the corresponding position of control medicinal material chromatogram on, show identical light blue white fluorescent spot;
B. get the quite described composition material medicine of preparation 3.5-4.5g, the 35ml that adds diethyl ether, ultrasonic Extraction 30 minutes filters, and filtrate volatilizes, and the 2ml that adds diethyl ether makes dissolving, as need testing solution; Get glutinous rehmannia control medicinal material 1.0g again, add the 20ml ether, ultrasonic Extraction 30 minutes filters, and filtrate volatilizes, and the control medicinal material solution that every 1ml contains 1.0g is made in the dissolving that adds diethyl ether; According to thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developping agent with lower floor's solution of 8: 2: 1 chloroform-methanol-ammoniacal liquor, launch, take out, dry; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
C. get the quite described composition material medicine of preparation 1.5-2.5g, porphyrize, 20ml adds diethyl ether, sonicated 20 minutes filters, and discards ether, residue is put water-bath Back stroke ether to the greatest extent, adds ethyl acetate 30ml, reflux 1 hour, take out, put coldly, filter, the dregs of a decoction volatilize ethyl acetate, add methyl alcohol 20ml, sonicated 20 minutes, filter, filtrate evaporate to dryness, residue add water 10ml makes dissolving, add 3 of strong ammonia solutions again, filter, filtrate adds 3 of hydrochloric acid, and is centrifugal, abandoning supernatant, precipitation adds methyl alcohol 2ml makes dissolving, filters, and filtrate is as test sample; Other gets the scutelloside reference substance, adds methyl alcohol and makes the solution that every 1ml contains 1mg, in contrast product solution; According to the thin-layered chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 5: 3: 1: 1 ethyl acetate-butanone-formic acid-water is developping agent, launches, and takes out, and dries, spray is with 1% ferric trichloride ethanolic solution; In the test sample chromatogram, with the corresponding position of reference substance chromatogram on, show the spot of same color;
Assay:
According to high effective liquid chromatography for measuring: chromatographic condition and system suitability test are filling agent with octadecylsilane chemically bonded silica; 10: 90 acetonitrile-waters are moving phase; The detection wavelength is 230nm; The preparation of reference substance solution: precision takes by weighing Paeoniflorin reference substance 5mg, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, shakes up, promptly; The preparation of need testing solution: get the preparation of quite described composition material medicine 3-4.5g, put in the tool plug conical flask, the accurate methyl alcohol 50ml that adds, close plug claims to decide weight, power 250W, frequency 40KHz sonicated 30 minutes is taken out, and puts cold, claim again to decide weight, supply the weight that subtracts mistake, filter with methyl alcohol, precision is measured subsequent filtrate 10ml, put in the 50ml volumetric flask and be diluted to scale, shake up, promptly with methyl alcohol; Determination method: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject liquid chromatograph, measure, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100987719A CN101293063B (en) | 2007-04-26 | 2007-04-26 | Composition for treating climacteric syndrome, preparation and quality control method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100987719A CN101293063B (en) | 2007-04-26 | 2007-04-26 | Composition for treating climacteric syndrome, preparation and quality control method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105380704A Division CN102000264B (en) | 2007-04-26 | 2007-04-26 | Detection method of composition for treating climacteric syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101293063A CN101293063A (en) | 2008-10-29 |
| CN101293063B true CN101293063B (en) | 2011-01-26 |
Family
ID=40063772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100987719A Active CN101293063B (en) | 2007-04-26 | 2007-04-26 | Composition for treating climacteric syndrome, preparation and quality control method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101293063B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461898B (en) * | 2008-12-29 | 2012-03-07 | 北京同仁堂股份有限公司 | Chinese medicine solid preparation for treating climacteric syndrome and preparation method thereof |
| CN102755521B (en) * | 2012-07-31 | 2014-01-29 | 施慧达药业集团(吉林)有限公司 | Chinese materia medica preparation for treating climacteric syndrome and preparation method thereof |
| CN104189442A (en) * | 2014-09-25 | 2014-12-10 | 崔银方 | Traditional Chinese medicine composition for treating menopausal syndrome |
| CN105699585B (en) * | 2016-02-05 | 2018-05-08 | 四川德成动物保健品有限公司 | Detection method for glutinous rehmannia in qingwen baidu powder |
| CN107233482A (en) * | 2017-06-13 | 2017-10-10 | 姚旺东 | A kind of Chinese medicine for treating insomnia palpitaition and climacteric metancholia |
| CN110575495A (en) * | 2019-09-29 | 2019-12-17 | 甘肃中医药大学 | traditional Chinese medicine compound preparation for preventing and treating perimenopausal syndrome and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679913A (en) * | 2005-02-03 | 2005-10-12 | 贵阳德昌祥药业有限公司 | Gynecologic rehabilitation capsules for treating gynecopathy |
| CN1785220A (en) * | 2005-12-09 | 2006-06-14 | 贵州益佰制药股份有限公司 | Method for quality control of blood-bonifying Chinese angelica prepn. |
-
2007
- 2007-04-26 CN CN2007100987719A patent/CN101293063B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679913A (en) * | 2005-02-03 | 2005-10-12 | 贵阳德昌祥药业有限公司 | Gynecologic rehabilitation capsules for treating gynecopathy |
| CN1785220A (en) * | 2005-12-09 | 2006-06-14 | 贵州益佰制药股份有限公司 | Method for quality control of blood-bonifying Chinese angelica prepn. |
Non-Patent Citations (1)
| Title |
|---|
| 药典委员会.坤宝丸.中华人民共和国卫生部药品标准中药成方制剂第6册.1992,76. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101293063A (en) | 2008-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101293063B (en) | Composition for treating climacteric syndrome, preparation and quality control method thereof | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN104873624B (en) | A kind of pharmaceutical composition for gouty arthritis | |
| CN101612312A (en) | The application of a kind of Chinese medicine composition in the diabetes complicated disease drug of preparation treatment | |
| CN102240318B (en) | Preparation method and analysis method of traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN102000264B (en) | Detection method of composition for treating climacteric syndrome | |
| CN101773561A (en) | Chinese medicine composition with functions of tonifying kidney, invigorating blood circulation and relieving pain and preparation method thereof | |
| CN101274035B (en) | Compositions for promoting blood circulation, menstruation and eliminating mass, preparation and quality control method | |
| CN102305839A (en) | Detection method of traditional Chinese medicine composition for freeing lung and relieving asthma | |
| CN103690782A (en) | Traditional Chinese medicine composition for treating climacteric syndrome, and preparation method and quality detection method thereof | |
| CN101966241A (en) | Method for detecting medicinal composition for treating cardiovascular and cerebrovascular diseases | |
| CN100563630C (en) | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation | |
| CN1806832B (en) | Pharmaceutical composition, its preparation process and quality control method | |
| CN1887324B (en) | Chinese medicine composition for treating liver and kidney defect, and its preparation process and analysis method | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN101439152B (en) | Chinese medicinal composition for treating cataract as well as preparation method | |
| CN102288701A (en) | Method for detecting Chinese medicinal composition for freeing lung and relieving asthma | |
| CN1899415B (en) | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN101564465A (en) | Chinese medicinal composition for nourishing blood, benefiting vital energy, regulating menstruation and dissipating cold | |
| CN102233071B (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN104096089B (en) | Traditional Chinese medicine composition for treating ischemia apoplexy, and capsules and preparation method thereof | |
| CN106728651A (en) | The preparation method and its method of quality control of a kind of rhizoma cyperi SIWU KELI | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN1331465C (en) | Blood stasis dispelling dripping pills for treating coronary heart disease, angina pectoris and hyperlipemia and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160226 Address after: 102600, Daxing District Zhongguancun science and Technology Park, Daxing pharmaceutical industry base, Tianhe West Road, No. 19, Beijing Patentee after: Beijing rich church Pharmaceutical Technology Co., Ltd. Address before: 102200, 8, Zhenxing Road, Zhongguancun science and Technology Park, Beijing, Changping District Patentee before: Beijing Asia-East Bio-Pharmaceutical Co., Ltd. |